Researchers conducted a retrospective cohort study to compare characteristics of children with a confirmed diagnosis of COVID-19, seasonal influenza A, and influenza B.
One-third of parents say they will forgo the flu vaccination for their children this year, despite public health recommendations.
Influenza vaccinations were found to be underutilized among groups who are considered to be at high risk for complications from infection.
When states lifted their stay-at-home orders, reopened businesses, and relaxed social distancing rules, the number of cases of COVID-19 exploded—what will happen when the flu season begins?
Influenza vaccination should occur by the end of October, if possible.
The Theraflu Home FluTest, a novel rapid influenza diagnostic test, demonstrated good sensitivity and specificity for both influenza A and B viruses.
Excess mortality during the peak of the 1918 H1N1 influenza pandemic was comparable to that seen early in the COVID-19 pandemic outbreak in New York City.
Following the initial pandemic wave of SARS-CoV-2 infections, it is unclear what trajectory of transition SARS-CoV-2 might take.
The Advisory Committee on Immunization Practices encourages all Americans to receive the flu vaccine between September and October.
The analysis included 241,551 patients monitored for a median of 4 years.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
In response to the COVID-19 pandemic, New York State implemented a series of community mitigation strategies, and monitoring approaches are needed to assess the effect of these interventions.
Targeting the elderly (individuals aged 65 years) for influenza vaccination may not decrease hospitalization or mortality rates in this population.
The adjuvanted, broad-spectrum influenza vaccine FLU-v was found to be immunogenic and merits phase 3 development to explore efficacy.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
The overall vaccine effectiveness against any influenza virus associated with medically attended ARI is 45% for the current season.
Fitbit data significantly improved prediction of influenza-like illness in top 5 states with most users.
Oseltamivir may reduce recovery time for primary care patients with influenza-like illness, especially for older, sicker patients with comorbidities.
Because of low vaccination rates, approximately 5.6 million cases of community-acquired pneumonia occur in the United States annually.